References
- Vanky E, Kjotrod S, Salvesen K A, Romundstad P, Moen M H, Carlsen S M. Clinical, biochemical and ultrasonographic characteristics of Scandinavian women with PCOS. Acta Obstet Gynecol Scand 2004; 83: 482–486
- Sozen I, Arici A. Hyperinsulinism and its interaction with hyperandrogenism in polycystic ovary syndrome. Obstet Gynecol Surv 2000; 55: 321–328
- Franks S. Polysytic ovary syndrome. N Engl J Med 1995; 333: 853–861
- Nestler J E, Poweres L P, Matt D W, Steingold K A, Plymate S R, Rittmaster R S, Clore J N, Blackard W G. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72: 83–89
- Velazquez E M, Mendoza S, Hamer T, Sosa F, Glueck C J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647–654
- Nestler J E, Jakubowicz D J, Evans W S, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338: 1876–1880
- Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 2001; 281: E392–E399
- Wu X K, Zhou S Y, Liu J X, Pollanen P, Sallinen K, Makinen M, Erkkola R. Selective ovarian resistance to insulin signaling in women with polycystic ovary syndrome. Fertil Steril 2003; 80: 954–965
- Velazquez E, Acosta A, Mendoza S G. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90: 392–395
- Fleming R, Hopkinson Z E, Wallace A M, Greer I A, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002; 87: 569–574
- Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, Lanzone A. Selective effects of pioglitazone on insulin and androgen abnormalities in normo and hyperinsulinemic obese patients with polycystic ovary syndrome. Hum Reprod 2003; 18: 1210–1218
- Glueck C J, Moreira A, Goldenberg N, Sieve L, Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003; 18: 1618–1625
- Garmes H M, Tambascia M A, Zanutut-Wittmann D E. Endocrine–metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005; 21: 317–323
- Katsuki A, Sumida Y, Gabazza E C, Murashima S, Furuta M, Araki-Sasaki R, Hori Y, Yano Y, Adachi Y. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 2001; 24: 362–365
- De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2002; 24: 633–667
- Genazzani A D, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Feril Steril 2004; 81: 114–119
- Maciel G A, Soares Junior J M, Alves da Motta E L, Abi Haidar M, de Lima G R, Baracat E C. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004; 81: 355–360
- Brettenthaler N, De Geyter C, Huber P R, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 3835–3840